Key result
High cardiometabolic risk profile is linked to ~22.6-fold higher incident heart failure risk over 4 years.
Why the study?
The combined effect of clustered cardiometabolic risk factors—obesity, dyslipidemia, and T2DM—on time-to-HF had rarely been quantified in young and middle-aged cohorts, particularly in Southeast Asia.
Does the clustering of cardiometabolic risk factors (obesity, dyslipidemia, and type 2 diabetes mellitus) reduce heart failure-free survival in young and middle-aged Indonesian adults aged 18–54 years?
Cohort (n=321)
Yes
Does the clustering of cardiometabolic risk factors (obesity, dyslipidemia, and type 2 diabetes mellitus) reduce heart failure-free survival in young and middle-aged Indonesian adults aged 18–54 years?
Clustering of obesity, dyslipidemia, and type 2 diabetes mellitus causes a steep, dose-dependent decline in 4-year heart failure-free survival among young and middle-aged Indonesian adults, with high-risk individuals facing a 22.59-fold increased hazard of developing heart failure.
Answers are grounded in this paper and cite their sources.
Cardiometabolic clustering signals high HF risk in young adults; leaves open whether modification alters incidence.
Background: Heart failure (HF) occurring in young and middle-aged adults carries a disproportionate health burden, yet HF epidemiology has traditionally emphasized older populations. Obesity, dyslipidemia, and type 2 diabetes mellitus (T2DM) are cardiometabolic risk factors for HF. Still, these factors commonly cluster within the same individual, and their combined effect on time-to-HF has rarely been quantified in young-onset cohorts, particularly in Southeast Asia. This study aimed to describe HF-free survival according to a simple cardiometabolic risk profile among adults aged 18–54 years.Methods: This study involved 321 patients aged 18–54 years without baseline heart failure, enrolled in 2021 across four tertiary hospitals in Indonesia. They were followed monthly until December 2024, with a maximum follow-up of 48 months. Participants were grouped into three cardiometabolic risk levels based on initial risk factors: low risk, moderate risk, and high risk. HF-free survival was assessed using the Kaplan–Meier method and compared among risk tiers via the log-rank test. Hazard ratios, both crude and adjusted for age and sex, were estimated with Cox proportional-hazards regression. Result: Ninety-two patients (28.7%) developed HF during follow-up (median follow-up 48 months, IQR 38–48). The cohort comprised 148 (46.1%) low-risk, 119 (37.1%) moderate-risk, and 54 (16.8%) high-risk patients. Four-year HF-free survival was 93.9% (95%CI 90.1–97.8) in the low-risk group, 62.2% (95%CI 53.5–70.9) in the moderate-risk group, and 29.6% (95%CI 17.5–41.8) in the high-risk group (log-rank χ2 = 106.2, df = 2, p<0.001). Incidence rates rose from 1.56 to 12.15 to 33.19 per 100 person-years across tiers. Compared with the low-risk group, the age/sex-adjusted hazard of HF was 7.47-fold higher (95%CI 3.65–15.30) in the moderate-risk group and 22.59-fold higher (95%CI 10.67–47.84) in the high-risk group. Each additional cardiometabolic risk factor was independently associated with a 3.14-fold increase in HF hazard (95% CI 2.44–4.03, p<0.001), consistent with a graded dose–response relationship. Conclusion: The clustering of obesity, dyslipidemia, and T2DM was linked to a sharp, progressive decrease in HF-free survival in young and middle-aged Indonesian adults. Counting coexisting cardiometabolic risk factors helps identify a small group at significantly higher short-term risk.
No takes yet. Share an insight, caveat, or question.
Rachmawan et al. (2026) conducted a cohort in Cardiometabolic risk for young-onset heart failure (n=321). High or moderate cardiometabolic risk profile (clustering of obesity, dyslipidemia, and type 2 diabetes mellitus) vs. Low cardiometabolic risk profile was evaluated on Heart failure-free survival (incident heart failure) at 4 years (HR 22.59, 95% CI 10.67-47.84, p=<0.001). High cardiometabolic risk profile sharply reduced 4-year HF-free survival vs low risk.
Synapse has enriched 10 related papers. Consider them for comparative context: